9 results about "Dioxetane" patented technology

This invention discloses a microRNA-responsive 1,2-dioxane-based chemiluminescent compound, its dual-probe system, kit, synthesis method, and applications. The compound's core is an o-acrylate-substituted phenoxyadamantane-1,2-dioxane, with the phenolic hydroxyl group protected by an azide benzyl group. The two-component probe system constructed based on this compound comprises an azide-modified first probe and a phosphine-modified second probe, each complementary to different segments of the target microRNA. Hybridization brings the two probes closer, triggering a Staudinger reaction to remove the protecting group and activate the chemiluminescent signal. This probe system requires no enzyme amplification or nucleic acid extraction, achieves a detection limit of 1.37 fM, and a signal-to-noise ratio as high as 157-fold. It can be successfully used for real-time imaging of endogenous microRNA-21 in live cells, showing broad application prospects in early tumor screening, auxiliary diagnosis, and prognostic assessment.

The invention discloses a microRNA (Ribonucleic Acid) response type 1, 2-dioxetane chemiluminescent compound as well as a double-probe system, a kit, a synthesis method and application thereof. The parent nucleus of the compound is o-acrylate substituted phenoxy adamantane-1, 2-dioxetane, and a phenolic hydroxyl group is protected by an azido benzyl group. A two-component probe system constructed based on the compound comprises a first azide-modified probe and a second phosphino-modified probe, the first azide-modified probe and the second phosphino-modified probe are respectively complementary with different sections of target microRNA, the two probes are pulled close through hybridization, a schudinger reaction is triggered to remove a protecting group, and a chemiluminescence signal is activated. The probe system does not need enzyme amplification and nucleic acid extraction, the detection limit reaches 1.37 fM, the signal-to-noise ratio reaches up to 157 times, and the probe system can be successfully used for real-time imaging of living cell endogenous microRNA-21 and has wide application prospects in the fields of early tumor screening, auxiliary diagnosis and prognosis evaluation.

The invention discloses a dioxetane chemiluminescent probe suitable for a biological orthogonal catalytic reaction as well as synthesis and application of the dioxetane chemiluminescent probe. A phenolic hydroxyl group active site of the probe is protected by an allyl bio-orthogonal cleavable group, and when a ruthenium metal complex catalyst is not added, the probe is in a silence state, and a chemiluminescence signal is weak; and in the presence of the ruthenium catalyst, the protecting group can be specifically catalytically cracked and removed, so that the probe is quickly activated and converted into a luminous'on 'state, and a strong chemiluminescence signal is generated. According to the invention, efficient combination of biological orthogonal cutting reaction and chemiluminescence signal output is realized, and the prepared biological orthogonal chemiluminescence probe has an excellent on-off ratio and is suitable for high-contrast biological imaging of living cell and living body levels.

Described herein are 1,2-dioxetane dimers that are useful as chemiluminescent probes, diagnostic agents, and imaging agents. Also described herein are compositions containing such compounds and methods of using the same.

The invention relates to the technical field of immunoassay, and discloses a chemiluminescence immunoassay method for high-sensitivity detection of cardiac troponin I. The chemiluminescence immunoassay method comprises the following steps: fixing an anti-cardiac troponin I capture antibody based on a solid phase carrier; a sample to be detected is in contact with the solid phase carrier coated with the capture antibody, a detection antibody is added, the detection antibody is connected with a signal marker, and the signal marker is a compound formed by loading alkaline phosphatase on a nano material or is the nano material; a chemiluminescent substrate is added, and the chemiluminescent substrate is a compound based on 1, 2-dioxetane; detecting a chemiluminescence signal so as to quantify cardiac troponin I; according to the invention, the problem of non-uniform detection of degradation fragments is solved, and the diagnosis window period is prolonged; meanwhile, extremely high detection sensitivity, signal-to-noise ratio and stability are realized, and the kit is suitable for early and accurate diagnosis of myocardial injury.

This invention relates to a class of dihydroxanthine chemiluminescent groups, their preparation methods, and applications. The dihydroxanthine chemiluminescent group developed in this invention, compared to the traditional phenolic dioxane chemiluminescent group which uses two rigid six-membered rings to fix the double bond conformation, exhibits a higher luminescence quantum yield and a longer emission wavelength. More importantly, it possesses a reactive aldehyde group, which, while maintaining high rigidity, extends the π-electron conjugated system, causing its emission wavelength to redshift to the near-infrared region. This allows it to be extended to chemiluminescence detection and in vivo imaging in small animal models.

Described herein are 1,2-dioxetane dimers that are useful as chemiluminescent probes, diagnostic agents, and imaging agents. Also described herein are compositions containing such compounds and methods of using the same.

The invention belongs to the technical field of medicinal chemistry, and particularly relates to a dioxetane-containing gold (III) complex as well as a preparation method and application thereof. The dioxetane-containing gold (III) complex provided by the invention can selectively release active gold in tumor cells under the condition of high-concentration GSH (glutathione), and the active gold can further react with GSH and other sulfydryl-containing molecules or proteins to inhibit the activity of the molecules or proteins and generate a strong anti-tumor effect; besides, the gold (III) complex provided by the invention can realize a good anti-tumor effect without using other prodrug activation strategies such as illumination activation or palladium-catalyzed biological orthogonal metallization reaction, and shows excellent inhibitory activity on various cancer cell lines; the compound has a wide application prospect in preparation of medicines for preventing and / or treating cancers.

The invention relates to a method of making a 1,2-dioxetane, the method comprising reacting a naphthalene endo peroxide (NEPO) with the double bond of an enol ether to form the 1,2-dioxetane. The 1,2-dioxetanes are of great commercial interest for a variety of applications, such as singlet oxygen detection, enzyme detection and pathogen (e.g., Salmonella spp. and Listeria spp.) detection.